GoHealth (GOCO) Cash & Equivalents (2019 - 2026)

GoHealth has disclosed Cash & Equivalents across 8 years of filings, most recently posting $39.9 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $39.9 million, up 80.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.9 million (up 80.02% YoY), and the FY2025 annual result was $32.9 million, down 19.59% from the prior year.
• Cash & Equivalents came in at $39.9 million for Q1 2026 at GoHealth, up from $32.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $215.4 million in Q3 2022 to a low of $14.1 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $35.5 million (2024), against an average of $56.7 million.
• Peak annual rise in Cash & Equivalents reached 451.56% in 2023, while the deepest fall reached 87.75% in 2023.
• GoHealth's Cash & Equivalents stood at $16.5 million in 2022, then surged by 451.56% to $90.8 million in 2023, then sank by 54.94% to $40.9 million in 2024, then decreased by 19.59% to $32.9 million in 2025, then climbed by 21.2% to $39.9 million in 2026.
• The last three Cash & Equivalents figures came in at $39.9 million (Q1 2026), $32.9 million (Q4 2025), and $32.1 million (Q3 2025), per Business Quant data.